Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Janet Ellsworth is active.

Publication


Featured researches published by Janet Ellsworth.


Arthritis Care and Research | 2010

Prevalent Vertebral Fractures among Children Initiating Glucocorticoid Therapy for the Treatment of Rheumatic Disorders

Adam M. Huber; Isabelle Gaboury; David A. Cabral; Bianca Lang; Andy Ni; David Stephure; Shayne Taback; Peter B. Dent; Janet Ellsworth; Claire LeBlanc; Claire Saint-Cyr; Rosie Scuccimarri; John Hay; Brian Lentle; M. Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski; Leanne M. Ward

Vertebral fractures are an under‐recognized problem in children with inflammatory disorders. We studied spine health among 134 children (87 girls) with rheumatic conditions (median age 10 years) within 30 days of initiating glucocorticoid therapy.


Arthritis Care and Research | 2012

Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study.

Celia Rodd; Bianca Lang; Timothy Ramsay; Nathalie Alos; Adam M. Huber; David A. Cabral; Rosie Scuccimarri; Paivi Miettunen; J. Roth; Stephanie A. Atkinson; Robert Couch; Elizabeth A. Cummings; Peter B. Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Maggie Larché; Claire LeBlanc; Kiem Oen; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Brian Lentle; M. Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski

To determine the frequency of incident vertebral fractures (IVF) 12 months after glucocorticoid (GC) initiation in children with rheumatic diseases and to identify children at higher risk.


Annals of the Rheumatic Diseases | 2015

The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort

Jaime Guzman; Kiem Oen; Lori B. Tucker; Adam M. Huber; Natalie J. Shiff; Gilles Boire; Rosie Scuccimarri; Roberta A. Berard; Shirley M. L. Tse; Kimberly Morishita; Elizabeth Stringer; Nicole Johnson; Deborah M. Levy; Karen Watanabe Duffy; David A. Cabral; Alan M. Rosenberg; Maggie Larché; Paul Dancey; Ross E. Petty; Ronald M. Laxer; Earl D. Silverman; Paivi Miettunen; Anne-Laure Chetaille; Elie Haddad; Kristin Houghton; Lynn Spiegel; Stuart E. Turvey; Heinrike Schmeling; Bianca Lang; Janet Ellsworth

Objective To describe clinical outcomes of juvenile idiopathic arthritis (JIA) in a prospective inception cohort of children managed with contemporary treatments. Methods Children newly diagnosed with JIA at 16 Canadian paediatric rheumatology centres from 2005 to 2010 were included. Kaplan–Meier survival curves for each JIA category were used to estimate probability of ever attaining an active joint count of 0, inactive disease (no active joints, no extraarticular manifestations and a physician global assessment of disease activity <10 mm), disease remission (inactive disease >12 months after discontinuing treatment) and of receiving specific treatments. Results In a cohort of 1104 children, the probabilities of attaining an active joint count of 0 exceeded 78% within 2 years in all JIA categories. The probability of attaining inactive disease exceeded 70% within 2 years in all categories, except for RF-positive polyarthritis (48%). The probability of discontinuing treatment at least once was 67% within 5 years. The probability of attaining remission within 5 years was 46–57% across JIA categories except for polyarthritis (0% RF-positive, 14% RF-negative). Initial treatment included joint injections and non-steroidal anti-inflammatory drugs for oligoarthritis, disease-modifying antirheumatic drugs (DMARDs) for polyarthritis and systemic corticosteroids for systemic JIA. Conclusions Most children with JIA managed with contemporary treatments attain inactive disease within 2 years of diagnosis and many are able to discontinue treatment. The probability of attaining remission within 5 years of diagnosis is about 50%, except for children with polyarthritis.


Arthritis Care and Research | 1999

Isometric strength measurements in children with arthritis: Reliability and relation to function

Jean Wessel; Cara Kaup; Jean Fan; Ross Ehalt; Janet Ellsworth; Coral Speer; Pat Tenove; Allison Dombrosky

OBJECTIVE To examine the reliability of testing strength in children with juvenile arthritis (JA), and to determine the relationship between strength and function. METHODS Children with JA were tested for grip and pinch strength (n = 32). Isometric force produced by hip abductors and knee extensors was tested with a hand-held dynamometer (n = 29). Two therapists both performed each of the tests twice so that intrarater and interrater reliability could be examined. Function was measured by means of the Childhood Health Assessment Questionnaire (CHAQ) and performance on a 50-meter run. Reliability was examined with intraclass correlations (ICC). The relationships of strength and function were determined with Pearson and Spearman correlations. RESULTS All measures demonstrated good intrarater (ICC = 0.92-0.97) and interrater (ICC = 0.80-0.95) reliability. Grip strength and pinch were correlated with the CHAQ (r = -0.45 and -0.33, respectively), while hip abduction and knee extension torque were correlated with rankings on the 50-meter run (rho = -0.34 and -0.38, respectively). CONCLUSION Isometric strength can be reliably measured in children with arthritis in a clinical setting.


Arthritis Care and Research | 2010

Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort

Kiem Oen; Ciarán M. Duffy; Shirley M. L. Tse; Suzanne Ramsey; Janet Ellsworth; Gaëlle Chédeville; Anne-Laure Chetaille; Claire Saint-Cyr; David A. Cabral; Lynn Spiegel; Rayfel Schneider; Bianca Lang; Adam M. Huber; Paul Dancey; Earl D. Silverman; Alan M. Rosenberg; Bonnie Cameron; Nicole Johnson; Jean Dorval; Rosie Scuccimarri; Sarah Campillo; Ross E. Petty; Karen Watanabe Duffy; Gilles Boire; Elie Haddad; Kristin Houghton; Ronald M. Laxer; Stuart E. Turvey; Paivi Miettunen; Katherine Gross

To determine early outcomes and early improvements in a prospective inception cohort of children with juvenile idiopathic arthritis (JIA) treated with current standard therapies.


Arthritis Care and Research | 2009

Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: Results of a Canadian multicenter, prospective inception cohort study

Kiem Oen; Lori B. Tucker; Adam M. Huber; Paivi Miettunen; Rosie Scuccimarri; Sarah Campillo; David A. Cabral; Brian M. Feldman; Shirley M. L. Tse; Gaëlle Chédeville; Lynn Spiegel; Rayfel Schneider; Bianca Lang; Janet Ellsworth; Suzanne Ramsey; Paul Dancey; Earl D. Silverman; Anne-Laure Chetaille; Bonnie Cameron; Nicole Johnson; Jean Dorval; Ross E. Petty; Karen Watanabe Duffy; Gilles Boire; Elie Haddad; Kristin Houghton; Claire Saint-Cyr; Stuart E. Turvey; Susanne M. Benseler; Mary Cheang

OBJECTIVE To determine early predictors of 6-month outcomes in a prospective cohort of patients with juvenile idiopathic arthritis (JIA). METHODS Patients selected were those enrolled in an inception cohort study of JIA, the Research in Arthritis in Canadian Children Emphasizing Outcomes Study, within 6 months after diagnosis. The juvenile rheumatoid arthritis core criteria set and quality of life measures were collected at enrollment and 6 months later. Outcomes evaluated included inactive disease, Juvenile Arthritis Quality of Life Questionnaire (JAQQ) scores, and Childhood Health Assessment Questionnaire (C-HAQ) scores at 6 months. RESULTS Thirty-three percent of patients had inactive disease at 6 months. Onset subtype and most baseline core criteria set measures correlated with all 3 outcomes. Relative to oligoarticular JIA, the risks of inactive disease were lower for enthesitis-related arthritis, polyarthritis rheumatoid factor (RF)-negative JIA, and polyarthritis RF-positive JIA, and were similar for psoriatic arthritis. In multiple regression analyses, the baseline JAQQ score was an independent predictor of all 3 outcomes. Other independent baseline predictors included polyarthritis RF-negative and systemic JIA for inactive disease; C-HAQ score and polyarthritis RF-positive JIA for the 6-month C-HAQ score; and active joint count, pain, and time to diagnosis for the 6-month JAQQ score. CONCLUSION Clinical measures soon after diagnosis predict short-term outcomes for patients with JIA. The JAQQ is a predictor of multiple outcomes. Time to diagnosis affects quality of life in the short term.


The Journal of Pediatrics | 1996

Seasonal onset of systemic-onset juvenile rheumatoid arthritis☆☆☆★

Brian M. Feldman; Nina Birdi; James E. Boone; Peter B. Dent; Ciarán M. Duffy; Janet Ellsworth; Bianca A. Lang; Ronald M. Laxer; Raymond M. Lewkonia; Peter N. Malleson; Kiem Oen; Julie D. Paquin; Alan M. Rosenberg; Rayfel Schneider; Earl D. Silverman

OBJECTIVE This study was undertaken to investigate the recent finding of a seasonal difference in the onset of systemic-onset juvenile rheumatoid arthritis (SoJRA). We hypothesized that a seasonal onset pattern might implicate on infectious agent as a cause of SoJRA. METHODS The date of onset was collected from the records of all patients with SoJRA from 1980 to 1992 at presentation to pediatric rheumatology clinics across Canada. The onset pattern of SoJRA was then compared with incidence data on viral infections obtained for the same period. RESULTS Across Canada the onset of SoJRA was constant across the seasons. However, in the Prairie region there was a statistically significant seasonal pattern, with peaks in autumn and early spring. We could find no evidence that viral incidence correlated with disease incidence either throughout Canada or in the Prairie region. CONCLUSIONS If a seasonal infectious agent causes SoJRA, then it is likely only one of several causes and may act only in certain regions. Future studies should be carried out in those areas where SoJRA does have a seasonal onset pattern.


The Journal of Rheumatology | 2016

Development of System-level Performance Measures for Evaluation of Models of Care for Inflammatory Arthritis in Canada

Claire E.H. Barber; Deborah A. Marshall; Dianne Mosher; Pooneh Akhavan; Lori B. Tucker; Kristin Houghton; Michelle Batthish; Deborah M. Levy; Heinrike Schmeling; Janet Ellsworth; Heidi Tibollo; Sean Grant; Dmitry Khodyakov; Diane Lacaille

Objective. To develop system-level performance measures for evaluating the care of patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. Methods. This study involved several methodological phases. Over multiple rounds, various participants were asked to help define a set of candidate measurement themes. A systematic search was conducted of existing guidelines and measures. A set of 6 performance measures was defined and presented to 50 people, including patients with IA, rheumatologists, allied health professionals, and researchers using a 3-round, online, modified Delphi process. Participants rated the validity, feasibility, relevance, and likelihood of use of the measures. Measures with median ratings ≥ 7 for validity and relevance were included in the final set. Results. Six performance measures were developed evaluating the following aspects of care, with each measure being applied separately for each type of IA except where specified: waiting times for rheumatology consultation for patients with new onset IA, percentage of patients with IA seen by a rheumatologist, percentage of patients with IA seen in yearly followup by a rheumatologist, percentage of patients with RA treated with a disease-modifying antirheumatic drug (DMARD), time to DMARD therapy in RA, and number of rheumatologists per capita. Conclusion. The first set of system-level performance measures for IA care in Canada has been developed with broad input. The measures focus on timely access to care and initiation of appropriate treatment for patients with IA, and are likely to be of interest to other arthritis care systems internationally.


Annals of the Rheumatic Diseases | 2016

The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort

Jaime Guzman; Kiem Oen; Adam M. Huber; Karen Watanabe Duffy; Gilles Boire; Natalie J. Shiff; Roberta A. Berard; Deborah M. Levy; Elizabeth Stringer; Rosie Scuccimarri; Kimberly Morishita; Nicole Johnson; David A. Cabral; Alan M. Rosenberg; Maggie Larché; Paul Dancey; Ross E. Petty; Ronald M. Laxer; Earl D. Silverman; Paivi Miettunen; Anne-Laure Chetaille; Elie Haddad; Kristin Houghton; Lynn Spiegel; Stuart E. Turvey; Heinrike Schmeling; Bianca Lang; Janet Ellsworth; Suzanne Ramsey; Alessandra Bruns

Objective To describe probabilities and characteristics of disease flares in children with juvenile idiopathic arthritis (JIA) and to identify clinical features associated with an increased risk of flare. Methods We studied children in the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) prospective inception cohort. A flare was defined as a recurrence of disease manifestations after attaining inactive disease and was called significant if it required intensification of treatment. Probability of first flare was calculated with Kaplan–Meier methods, and associated features were identified using Cox regression. Results 1146 children were followed up a median of 24 months after attaining inactive disease. We observed 627 first flares (54.7% of patients) with median active joint count of 1, physician global assessment (PGA) of 12 mm and duration of 27 weeks. Within a year after attaining inactive disease, the probability of flare was 42.5% (95% CI 39% to 46%) for any flare and 26.6% (24% to 30%) for a significant flare. Within a year after stopping treatment, it was 31.7% (28% to 36%) and 25.0% (21% to 29%), respectively. A maximum PGA >30 mm, maximum active joint count >4, rheumatoid factor (RF)-positive polyarthritis, antinuclear antibodies (ANA) and receiving disease-modifying antirheumatic drugs (DMARDs) or biological agents before attaining inactive disease were associated with increased risk of flare. Systemic JIA was associated with the lowest risk of flare. Conclusions In this real-practice JIA cohort, flares were frequent, usually involved a few swollen joints for an average of 6 months and 60% led to treatment intensification. Children with a severe disease course had an increased risk of flare.


The Journal of Rheumatology | 2014

Diagnostic Utility of Magnetic Resonance Imaging and Radiography in Juvenile Spondyloarthritis: Evaluation of the Sacroiliac Joints in Controls and Affected Subjects

Jacob L. Jaremko; Lei Liu; Naomi Winn; Janet Ellsworth; R.G. Lambert

Objective. To compare the utility of radiography and magnetic resonance imaging (MRI) for the diagnosis of juvenile-onset spondyloarthritis in pediatric patients presenting with low back and/or sacroiliac (SI) pain of potentially inflammatory etiology. Methods. Radiographs and MRI studies of the SI joints in 26 patients with juvenile spondyloarthritis (JSpA) and 35 controls were assessed independently by 2 radiologists, with discrepancies arbitrated by a third. Radiographs and MRI were blinded and read in separate batches in random order. Results. Erosion was common and was the most useful diagnostic feature on radiography [positive likelihood ratio (LR) = 3.5] and was especially diagnostic of SpA on MRI (LR = 6.7). Subchondral sclerosis was common but was the least specific feature for both modalities. Joint space narrowing had some utility on radiography (LR = 2.0) and MRI (LR = 2.7) but was uncommon and had poor reader reliability. Bone marrow edema (LR = 3.1) and subarticular fat infiltration (LR = 4.5), detectable only on MRI, were both useful features. Global diagnostic impression of MRI (LR = 9.4) had very high utility for the diagnosis of JSpA, exceeding radiography (LR = 4.4) because of superior specificity. In addition, global diagnosis of SpA is much more reliably made on MRI (κ = 0.80) compared to radiography (κ = 0.30). Conclusion. Specificity and reliability of MRI of the SI joints are superior to radiography for the diagnosis of juvenile-onset SpA and, where available, MRI should replace radiography as the first line of investigation.

Collaboration


Dive into the Janet Ellsworth's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kristin Houghton

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kiem Oen

University of Manitoba

View shared research outputs
Top Co-Authors

Avatar

David A. Cabral

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jaime Guzman

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge